Improved cisplatin delivery in cervical cancer cells by utilizing folate-grafted non-aggregated gelatin nanoparticles

Biomedicine and Pharmacotherapy

Volumn 69, Issue , 2015, Pages 1-10

  Dixit, Nishu ^a   Vaibhav, Kumar ^b   Pandey, Ravi Shankar ^c   Jain, Upendra Kumar ^a   Katare, Om Prakash ^d   Katyal, Anju ^b   Madan, Jitender ^a  

^a Chandigarh College of Pharmacy   (India)

^b UNIVERSITY OF DELHI   (India)

^c GURU GHASIDAS UNIVERSITY   (India)

^d PANJAB UNIVERSITY   (India)

Author keywords

Apoptosis; Cellular uptake; Cervical cancer; Cisplatin; Cytotoxicity; Folate; Gelatin nanoparticles

Indexed keywords

AMINE; CISPLATIN; FOLATE RECEPTOR 1; FOLIC ACID; GELATIN; NANOCARRIER; NANOCONJUGATE; NON AGGREGATED FOLIC ACID CONJUGATED GELATIN NANOPARTICLE; UNCLASSIFIED DRUG; NANOPARTICLE; POWDER;

A549 CELL LINE; APOPTOSIS; ARTICLE; CELL NUCLEUS; CONFOCAL LASER MICROSCOPY; CONJUGATION; CONTROLLED STUDY; CYTOPLASM; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG UPTAKE; ENDOCYTOSIS; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; IC50; INFRARED SPECTROSCOPY; INTERNALIZATION; NANOENCAPSULATION; NANOFABRICATION; PARTICLE SIZE; PH; PRIORITY JOURNAL; SOLVATION; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL; CELL DEATH; CHEMISTRY; DRUG EFFECTS; KINETICS; POWDER; STATIC ELECTRICITY; ULTRASTRUCTURE; UTERINE CERVICAL NEOPLASMS;

APOPTOSIS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL DEATH; CISPLATIN; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FEMALE; FOLIC ACID; GELATIN; HELA CELLS; HUMANS; KINETICS; NANOPARTICLES; PARTICLE SIZE; POWDERS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STATIC ELECTRICITY; UTERINE CERVICAL NEOPLASMS; X-RAY DIFFRACTION;

EID: 84922264010     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.10.016     Document Type: Article

References (51)

1. Saito I., Kitagawa R., Fukuda H., Shibata T., Katsumata N., Konishi I., et al. A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: gynecologic cancer study group/Japan clinical oncology group study (JCOG0505). Jpn J Clin Oncol 2010, 40:90-93.
2. Maccio A., Madeddu C. Cisplatin: an old drug with a newfound efficacy-from mechanisms of action to cytotoxicity. Exp Opin Pharmacother 2013, 14:1839-1857.
3. Liu Y., Xing H., Han X., Shi X., Liang F., Cheng G., et al. Apoptosis of HeLa cells induced by cisplatin and its mechanism. J Huazhong Univ Sci Technolog Med Sci 2008, 28:197-199.
4. Zlatanova J., Yaneva J., Leuba S.H. Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin. FASEB J 1998, 12:791-799.
5. Go R.S., Adjei A.A. Comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999, 17:409-422.
6. Ozaki T., Ishiguro S., Itoh H., Furuhama K., Nakazawa M., Yamashita T. Cisplatin binding and inactivation of mitochondrial glutamate oxaloacetate transaminase in cisplatin-induced rat nephrotoxicity. Biosci Biotechnol Biochem 2013, 77:1645-1649.
7. da Silva Machado C., Mendonca V.de.P.V., Bianchi M.L., Antunes L.M. Coenzyme Q10 protects Pc12 cells from cisplatin-induced DNA damage and neurotoxicity. Neurotoxicol 2013, 36:10-16.
8. Langer T., Zehnhoff-Dinnesen A.A., Radtke S., Meitert J., Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci 2013, 34:458-469.
9. Talelli M., Oliveira S., Rijcken C.J., Pieters E.H., Etrych T., Ulbrich K., et al. Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. Biomaterials 2013, 34:1255-1260.
10. Wang L., Li M., Zhang N. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy. Int J Nanomedicine 2012, 7:3281-3294.
11. Sugiyama T., Asai T., Nedachi Y.M., Katanasaka Y., Shimizu K., Maeda N., et al. Enhanced active targeting via cooperative binding of ligands on liposomes to target receptors. PLoS ONE 2013, 8:e67550.
12. Cheng J., Gu Y.J., Cheng S.H., Wong W.T. Surface functionalized gold nanoparticles for drug delivery. J Biomed Nanotechnol 2013, 9:1362-1369.
13. Chen J., Shao R., Zhang X.D., Chen C. Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. Int J Nanomedicine 2013, 8:2677-2688.
14. Madan J., Pandey R.S., Jain V., Katare O.P., Chandra R., Katyal A. Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomedicine 2012, 9:492-503.
15. Garg M., Madan J., Pandey R.S., Sardana S., Katyal A., Chandra R. Galactosylated gelatin nanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells. Anticancer Drugs 2012, 23:836-845.
16. Chandra R., Madan J., Singh P., Chandra A., Kumar P., Tomar V., et al. Implications of nanoscale based drug delivery systems in delivery and targeting tubulin binding agent, noscapine in cancer cells. Curr Drug Metab 2012, 13:1476-1483.
17. Iyer A.K., Singh A., Ganta S., Amiji M.M. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev 2013, 65:1784-1802.
18. Bothun G.D., Lelis A., Chen Y., Scully K., Anderson L.E., Stoner M.A. Multicomponent folate-targeted magnetoliposomes: design, characterization, and cellular uptake. Nanomedicine 2011, 7:797-805.
19. Della-Longa S., Arcovito A. Structural and functional insights on folate receptor α (FR-α) by homology modeling, ligand docking and molecular dynamics. J Mol Graph Model 2013, 44C:197-207.
20. Barz M., Canal F., Koynov K., Zentel R., Vicent M.J. Synthesis and in vitro evaluation of defined HPMA folate conjugates: influence of aggregation on folate receptor (FR) mediated cellular uptake. Biomacromol 2010, 11:2274-2282.
21. Chen H., Zhang T., Zhou Z., Guan M., Wang J., Liu L., et al. Enhanced uptake and cytotoxity of folate-conjugated mitoxantrone-loaded micelles via receptor up-regulation by dexamethasone. Int J Pharm 2013, 448:142-149.
22. Yoo H.S., Park T.G. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release 2004, 100:247-256.
23. Zhao X., Li H., Lee R.J. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 2008, 5:309-319.
24. Madan J., Dhiman N., Sardana S., Aneja R., Chandra R., Katyal A. Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. Anticancer Drugs 2011, 22:543-555.
25. Madan J., Pandey R.S., Jain U.K., Katare O.P., Aneja R., Katyal A. Sterically-stabilized gelatin microassemblies of noscapine enhance cytotoxicity, apoptosis and drug delivery in lung cancer cells. Colloids Surf B Biointerface 2013, 107:235-244.
26. Chacon M., Molpeceres J., Berges L., Guzman M., Aberturas M.R. Stability and freeze-drying of cyclosporine loaded poly (D,L lactide-glycolide) carriers. Eur J Pharm Sci 1999, 8:99-107.
27. Maiorano G., Sabella S., Sorce B., Brunetti V., Malvindi M.A., Cingolani R., et al. Effects of cell culture media on the dynamic formation of protein-nanoparticle complexes and influence on the cellular response. ACS Nano 2010, 4:7481-7491.
28. Jain S., Mathur R., Das M., Swarnakar N.K., Mishra A.K. Synthesis, pharmacoscintigraphic evaluation and antitumor efficacy of methotrexate-loaded, folate-conjugated, stealth albumin nanoparticles. Nanomedicine (London) 2011, 6:1733-1754.
29. Shena Z., Li Y., Kohama K., Oneill B., Bi J. Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres. J Pharmacol Res 2011, 63:51-58.
30. Kale R., Bajaj A. Ultraviolet spectrophotometric method for determination of gelatin cross-linking in the presence of amino groups. J Young Pharmacist 2010, 2:90-94.
31. Madan J., Kaushik D., Sardana S., Ali A., Sudhakaran S.M., Pandey S.R. Effect of levofloxacin and pefloxacin on humoral immune response elicited by bovine serum albumin docked in gelatin nanoparticles and microparticles. Pharmazie 2010, 65:284-289.
32. Guo H., Qian H., Sun S., Sun D., Yin H., Cai X., et al. Hollow mesoporous silica nanoparticles for intracellular delivery of fluorescent dye. Chem Central J 2011, 5:1-10.
33. Devi S.V., Prakash T. Kinetics of cisplatin release by in vitro using poly (D,L lactide) coated Fe3O4 nanocarriers. IEEE Trans Nanobiosci 2013, 12:60-63.
34. Wy A., Garkhal K., Kumar N. Doxorubicin loaded (PEG) (3)-PLA nanopolymersomes: effect of solvents and process parameters on formulation development and in vitro study. Mol Pharm 2011, 8:466-478.
35. Gerweck L.E., Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 1996, 56:1194-1198.
36. Seidlitz A., Weitschies W. In vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing. J Pharm Pharmacol 2012, 64:969-985.
37. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1993, 65:55-63.
38. Dhar S., Liu Z., Thomale J., Dai H., Lippard S.J. Targeted single wall carbon nanotube mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc 2008, 130:11467-11476.
39. Kader A., Liu H. Interference of anthracycline derivatives with measurement of proteins with BCA. Clin Chem 1997, 43:2201-2202.
40. Yallapu M.M., Jaggi M., Chauhan S.C. β-Cyclodextrin-curcumin self assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf B Biointerfaces 2010, 79:113-125.
41. Zhang J., Chen Xi G., Peng W.B., Liu C.S. Uptake of oleoyl-chitosan nanoparticles by A549 cells. Nanomedicine 2008, 4:208-214.
42. Win K.Y., Feng S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26:2713-2722.
43. Rampino A., Borgogna M., Blasi P., Bellich B., Cesaro A. Chitosan nanoparticles: preparation, size evolution and stability. Int J Pharm 2013, 455:219-228.
44. Li Q., Liu C., Zhao X., Zu Y., Wang Y., Zhang B., et al. Preparation, characterization and targeting of micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells. Int J Nanomedicine 2011, 6:397-405.
45. Curnis F., Sacchi A., Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002, 110:475-482.
46. Minchinton A.I., Tannock I.F. Drug penetration in solid tumors. Nat Rev Cancer 2006, 6:583-592.
47. Dong Y., Feng S.S. Methoxy poly (ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004, 25:2843-2849.
48. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998, 95:4607-4612.
49. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnol 2007, 2:751-760.
50. Yang S.C., Lu L.F., Cai Y., Zhu J.B., Liang B.W., Yang C.Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999, 59:299-307.
51. Park E.K., Kim S.Y., Lee S.B., Lee Y.M. Folate-conjugated methoxy poly(ethylene glycol)/poly(-caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery. J Control Release 2005, 109:158-168.